A 12-month, Prospective, Randomized, Dual Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of Myfortic (R) (Mycophenolic Acid) Loading Regimens in Combination With Thymoglobulin (R) [Anti-thymocyte Globulin (Rabbit)] or Simulect (R) (Basiliximab) Induction and Prograf (R) (Tacrolimus) in Early Corticosteroid Withdrawal

Trial Profile

A 12-month, Prospective, Randomized, Dual Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of Myfortic (R) (Mycophenolic Acid) Loading Regimens in Combination With Thymoglobulin (R) [Anti-thymocyte Globulin (Rabbit)] or Simulect (R) (Basiliximab) Induction and Prograf (R) (Tacrolimus) in Early Corticosteroid Withdrawal

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Mycophenolate sodium (Primary) ; Antithymocyte globulin; Basiliximab; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 May 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
    • 18 Jun 2012 Planned end date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
    • 18 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top